A Phase 2 proof-of-concept study evaluating effect of VX-407 in people with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs VX 407 (Primary)
- Indications Polycystic kidney disease
- Focus Proof of concept; Therapeutic Use
- 16 Jan 2025 New trial record
- 12 Jan 2025 According to Vertex pharmaceuticals media release, this trial is expected to advance in 2025